Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects.
In a previous clinical study, a probiotic formulation (PF) consisting of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 (PF) decreased stress-induced gastrointestinal discomfort. Emerging evidence of a role for gut microbiota on central nervous system functions therefore suggests that oral intake of probiotics may have beneficial consequences on mood and psychological distress. The aim of the present study was to investigate the anxiolytic-like activity of PF in rats, and its possible effects on anxiety, depression, stress and coping strategies in healthy human volunteers. In the preclinical study, rats were daily administered PF for 2 weeks and subsequently tested in the conditioned defensive burying test, a screening model for anti-anxiety agents. In the clinical trial, volunteers participated in a double-blind, placebo-controlled, randomised parallel group study with PF administered for 30 d and assessed with the Hopkins Symptom Checklist (HSCL-90), the Hospital Anxiety and Depression Scale (HADS), the Perceived Stress Scale, the Coping Checklist (CCL) and 24 h urinary free cortisol (UFC). Daily subchronic administration of PF significantly reduced anxiety-like behaviour in rats (P < 0·05) and alleviated psychological distress in volunteers, as measured particularly by the HSCL-90 scale (global severity index, P < 0·05; somatisation, P < 0·05; depression, P < 0·05; and anger-hostility, P < 0·05), the HADS (HADS global score, P < 0·05; and HADS-anxiety, P < 0·06), and by the CCL (problem solving, P < 0·05) and the UFC level (P < 0·05). L. helveticus R0052 and B. longum R0175 taken in combination display anxiolytic-like activity in rats and beneficial psychological effects in healthy human volunteers.
Messaoudi
Michaël
M
ETAP-Ethologie Appliquée, Département de neuropsychopharmacologie 13 rue du Bois de la Champelle, Vandoeuvre-lès-Nancy, France. mmessaoudi@etap-lab.com
Lalonde
Robert
R
Violle
Nicolas
N
Javelot
Hervé
H
Desor
Didier
D
Nejdi
Amine
A
Bisson
Jean-François
JF
Rougeot
Catherine
C
Pichelin
Matthieu
M
Cazaubiel
Murielle
M
Cazaubiel
Jean-Marc
JM
D000223:Adaptation, Psychological / Q000187:drug effects*; D000328:Adult; D000786:Anger / Q000187:drug effects; D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology / Q000627:therapeutic use; D001007:Anxiety / Q000188:drug therapy*; D001644:Bifidobacterium; D003863:Depression / Q000188:drug therapy; D004311:Double-Blind Method; D005260:Female; D006791:Hostility; D006801:Humans; D052198:Lactobacillus helveticus; D008297:Male; D008875:Middle Aged; D019936:Probiotics / Q000494:pharmacology / Q000627:therapeutic use*; D011619:Psychotropic Drugs / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D012720:Severity of Illness Index; D013001:Somatoform Disorders / Q000188:drug therapy; D013315:Stress, Psychological / Q000188:drug therapy*
D014151:Anti-Anxiety Agents; D011619:Psychotropic Drugs